Adherence to Healthy Diet Improves Cardiometabolic Risk, Even Without Weight Loss
WEDNESDAY, June 11, 2025 -- A healthy diet improves cardiometabolic risk factors, even if not associated with weight loss (WL), according to a study published online June 5 in the European Journal of Preventive Cardiology.
Anat Yaskolka Meir, Ph.D., from Ben-Gurion University of the Negev in Beer-Sheva, Israel, and colleagues pooled data from three large long-term lifestyle WL-intervention trials, including the 24-month DIRECT (322 participants), 18-month CENTRAL (278 participants), and 18-month DIRECT PLUS (294 participants), to assess longitudinal changes in cardiometabolic risk markers.
The researchers found that among 761 trial completers, mean WL was −3.3 kg (−3.5 percent). Participants classified as successful-WL (relative-WL >5 percent) achieved the greatest improvements in multiple health indicators. However, the WL-resistant, who did not lose or gain weight, also showed some significant improvements, with increased high-density lipoprotein cholesterol (HDLc) and decreased leptin and visceral fat. Each 1-kg sustained lifestyle-induced WL was associated with improvements in lipid markers and insulin resistance (HDLc: +1.44 percent; triglycerides: −1.37 percent; insulin: −2.46 percent; HOMA-IR: −2.71 percent; leptin: −2.79 percent; intrahepatic-fat regression: −0.49 absolute-units). Each 1-kg sustained lifestyle-induced WL was also associated with modest but significant change in systolic and diastolic blood pressures (−0.26 and −0.36 percent, respectively).
"Our findings reframe how we define clinical success," Meir said in a statement. "People who do not lose weight can improve their metabolism and reduce their long-term risk for disease. That's a message of hope, not failure."
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
WEDNESDAY, Oct. 1, 2025 -- People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated...
Patients With Extreme Obesity Face Limitations to Accessing Specialty Care
TUESDAY, Sept. 30, 2025 -- Patients weighing more than 450 lb face considerable limitations when attempting to access specialty care, according to a research letter published...
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
TUESDAY, Sept. 30, 2025 -- Patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have better long-term outcomes compared with those taking...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.